EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability

Pei Li, Julia N Faraone, Cheng Chih Hsu, Michelle Chamblee, Yajie Liu, Yi-Min Zheng, Yan Xu, Claire Carlin, Jeffrey C Horowitz, Rama K Mallampalli, Linda J Saif iD, Eugene M Oltz und 6 weitere

Journal of Virology · 2025

DOI: 10.1128/jvi.00242-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Pei Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Retrovirus Research, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Immune Evasion, COVID-19. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, producing new variants that drive global coronavirus disease 2019 surges. XEC, a recombinant of KS.1.1 and KP.3.3, contains T22N and F59S mutations in the spike protein’s N-terminal domain (NTD). The T22N mutation, similar to the DelS31 mutation in KP.3.1.1, introduces a potential N-linked glycosylation site in XEC. In this study, we examined the neutralizing antibody (nAb) response and mutation effects in sera from bivalent-vaccinated healthcare workers, BA.2.86/JN.1 wave-infected patients, and XBB.1.5 monovalent-vaccinated hamsters, assessing responses to XEC alongside D614G, JN.1, KP.3, and KP.3.1.1. XEC demonstrated significantly reduced neutralization titers across all cohorts, largely due to the F59S mutation. Notably, removal of glycosylation sites in XEC and KP.3.1.1 substantially restored nAb titers. Antigenic cartography analysis revealed XEC to be more antigenically distinct from its common ancestral BA.2.86/JN.1 compared to KP.3.1.1, with the F59S mutation as a determining factor. Similar to KP.3.1.1, XEC showed reduced cell-cell fusion relative to its parental KP.3, a change attributed to the T22N glycosylation. We also observed reduced S1 shedding for XEC and KP.3.1.1, which was reversed by ablation of T22N and DelS31 glycosylation mutations, respectively. Molecular modeling suggests that T22N and F59S mutations of XEC alter hydrophobic interactions with adjacent spike protein residues, impacting both conformational stability and neutralization. Overall, our findings underscore the pivotal role of NTD mutations in shaping SARS-CoV-2 spike biology and immune escape mechanisms. IMPORTANCE The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the emergence of novel variants with enhanced immune evasion properties, posing challenges for current vaccination strategies. This study identifies key N-terminal domain (NTD) mutations, particularly T22N and F59S in the recent XEC variant, which significantly impacts antigenicity, neutralization, and spike protein stability. The introduction of an N-linked glycosylation site through T22N, along with the antigenic shift driven by F59S, highlights how subtle mutations can drastically alter viral immune recognition. By demonstrating that glycosylation site removal restores neutralization sensitivity, this work provides crucial insights into the molecular mechanisms governing antibody escape. Additionally, the observed effects on spike protein shedding and cell-cell fusion contribute to a broader understanding of variant fitness and transmissibility. These findings emphasize the importance of monitoring NTD mutations in emerging SARS-CoV-2 lineages and support the need for adaptive vaccine designs to counteract ongoing viral evolution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2Immune EvasionCOVID-19GlycosylationAnimalsAntibodies, NeutralizingHumansMutationAntibodies, ViralCricetinaeCell FusionProtein DomainsCOVID-19 Vaccines

Stichwörter der Autor:innen

NTD mutationSARS-CoV-2XEC variantglycosylationimmune evasionneutralizing antibody escapespike protein stability

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, Neutralizingspike protein, SARS-CoV-2Antibodies, ViralCOVID-19 Vaccines

Autor:innen und Institutionen

  • Center for Retrovirus Research, The Ohio State University, Columbus, Ohio, USA.
  • Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
  • Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, Ohio, USA.
  • Texas Therapeutic Institute, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Department of Internal Medicine, Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine,The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Linda J Saif, Jianrong Li, Shan-Lu Liu

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NICHD NIH HHS

Zitieren

APA

Li, P., Faraone, J. N., Hsu, C. C., Chamblee, M., Liu, Y., Zheng, Y. M., Xu, Y., Carlin, C., Horowitz, J. C., Mallampalli, R. K., Saif, L. J., Oltz, E. M., Jones, D., Li, J., Gumina, R. J., Bednash, J. S., Xu, K., & Liu, S. L. (2025). Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability. Journal of Virology. https://doi.org/10.1128/jvi.00242-25

Vancouver

Li P, Faraone JN, Hsu CC, Chamblee M, Liu Y, Zheng YM, et al. Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability. Journal of Virology. 2025. doi:10.1128/jvi.00242-25

BibTeX
@article{Li2025,
  author = {Li, Pei and Faraone, Julia N and Hsu, Cheng Chih and Chamblee, Michelle and Liu, Yajie and Zheng, Yi-Min and Xu, Yan and Carlin, Claire and Horowitz, Jeffrey C and Mallampalli, Rama K and Saif, Linda J and Oltz, Eugene M and Jones, Daniel and Li, Jianrong and Gumina, Richard J and Bednash, Joseph S and Xu, Kai and Liu, Shan-Lu},
  title = {Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.00242-25}
}
Kostenlos starten →